Wilson W. Wong

This study develops a tunable OR-gated CAR system for AML treatment that effectively targets multiple antigens with reduced engineering complexity and minimized off-target toxicity.

This paper introduces a high-throughput 3D microtissue platform for analyzing tissue remodeling dynamics, showing it better aligns with clinical outcomes than 2D assays.

This study develops a modified self-amplifying RNA-based BiTE system that provides long-term B cell clearance with a single injection.

This paper develops a self-amplifying RNA platform for CAR T cells that improves durability and enables multi-genic logic functions, showing superior tumor suppression in a leukemia model.

This study shows that modulating cholesterol metabolism in ovarian cancer cells enhances CAR-T cell cytotoxicity by disrupting lipid storage mechanisms.

This paper demonstrates that modified self-amplifying RNA (saRNA) enables long-lasting protein expression in mouse and human brain tissues.

This paper introduces a framework for model-informed mRNA design using integrated gradients and an agentic hypothesis engine, achieving improved in vivo expression.

The paper develops a library of red light-inducible recombinases and uses them with the BLADE platform to control cell fate, Boolean logic, and cell patterning in mammalian cells.

This paper introduces a method to spatially control cell fate using optogenetic recombinase switches and precise illumination, enabling high-resolution patterning of heterogeneous cell populations.

The paper introduces CRIBOS, a cell-free genetic circuit platform for multiplex Boolean logic, demonstrating environmental sensing and long-term DNA memory storage.

This paper introduces CRISTAL, a platform for programmable RNA regulation using inducible Cas13 circuits, enabling precise temporal control and multiplexed gene regulation in mammalian cells.

This study uses longitudinal single-cell chemical imaging to reveal fatty acid production heterogeneity in engineered E. coli strains over time.

This paper designs synthetic gene regulatory programs for human cells that can be controlled by FDA-approved drugs and demonstrate therapeutic applications in immune cells.

The paper develops drug-gated CAR circuits using NS3 protease domains and FDA-approved inhibitors to enhance CAR T cell therapy safety and specificity.

This paper introduces CREATE, a genetic circuit platform that enables complex signal processing in mammalian cells through programmable transcription factors and site-specific recombination.

This paper introduces a modular recombinase-based gene circuit that enables sequential gene expression using two ligands and applies it to model multi-stage genetic changes.

The paper develops a mechanistic model of the BLADE platform to predict performance of 256 synthetic DNA recombination circuits, showing good agreement with experimental data and identifying factors affecting circuit performance.

The paper introduces a library of inducible split recombinases for precise and multiplexed gene expression control in mammalian cells and mice.

This paper introduces gene circuits with memory to control gene expression in T cells, demonstrating regulation of CAR expression and T cell activity using an FDA-approved drug.